Eckert & Ziegler SE (FRA:EUZ)

Market Cap	914.21M -22.9%
Revenue (ttm)	304.47M +9.6%
Net Income	39.75M +35.3%
EPS	0.63 +34.6%
Shares Out	n/a
PE Ratio	23.00
Forward PE	17.49
Dividend	0.17 (1.16%)
Ex-Dividend Date	Jun 19, 2025

Volume	420
Average Volume	210
Open	14.99
Previous Close	15.01
Day's Range	14.42 - 14.99
52-Week Range	13.49 - 23.00
Beta	n/a
RSI	46.59
Earnings Date	Mar 26, 2026

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-co...

• Industry: Industrial Inorganic Chemicals
• Founded: 1992
• Employees: 1,112
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EUZ

Financial Performance

In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.